Zentalis Pharmaceuticals (ZNTL) Competitors $1.76 -0.06 (-3.30%) Closing price 04:00 PM EasternExtended Trading$1.83 +0.07 (+3.98%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZNTL vs. ANAB, SVRA, SAGE, RAPP, KOD, ARVN, SEPN, GOSS, ZVRA, and OPTShould you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include AnaptysBio (ANAB), Savara (SVRA), Sage Therapeutics (SAGE), Rapport Therapeutics (RAPP), Kodiak Sciences (KOD), Arvinas (ARVN), Septerna (SEPN), Gossamer Bio (GOSS), Zevra Therapeutics (ZVRA), and Opthea (OPT). These companies are all part of the "pharmaceutical products" industry. Zentalis Pharmaceuticals vs. Its Competitors AnaptysBio Savara Sage Therapeutics Rapport Therapeutics Kodiak Sciences Arvinas Septerna Gossamer Bio Zevra Therapeutics Opthea AnaptysBio (NASDAQ:ANAB) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends. Which has more volatility and risk, ANAB or ZNTL? AnaptysBio has a beta of -0.2, indicating that its stock price is 120% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Do analysts recommend ANAB or ZNTL? AnaptysBio currently has a consensus price target of $46.13, indicating a potential upside of 129.14%. Zentalis Pharmaceuticals has a consensus price target of $8.20, indicating a potential upside of 365.91%. Given Zentalis Pharmaceuticals' higher probable upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than AnaptysBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AnaptysBio 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80Zentalis Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.67 Which has stronger valuation and earnings, ANAB or ZNTL? AnaptysBio has higher revenue and earnings than Zentalis Pharmaceuticals. AnaptysBio is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnaptysBio$91.28M6.17-$145.23M-$4.48-4.49Zentalis Pharmaceuticals$67.43M1.88-$165.84M-$2.26-0.78 Does the media refer more to ANAB or ZNTL? In the previous week, AnaptysBio and AnaptysBio both had 4 articles in the media. AnaptysBio's average media sentiment score of 1.09 beat Zentalis Pharmaceuticals' score of 0.54 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zentalis Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ANAB or ZNTL more profitable? Zentalis Pharmaceuticals has a net margin of 0.00% compared to AnaptysBio's net margin of -107.66%. Zentalis Pharmaceuticals' return on equity of -51.62% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets AnaptysBio-107.66% -366.98% -30.58% Zentalis Pharmaceuticals N/A -51.62%-40.28% SummaryAnaptysBio beats Zentalis Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZNTL vs. The Competition Export to ExcelMetricZentalis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$131.29M$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-0.7821.0831.2626.59Price / Sales1.88364.13454.13168.41Price / CashN/A44.6737.7359.36Price / Book0.468.0910.046.68Net Income-$165.84M-$54.08M$3.27B$265.59M7 Day Performance-5.88%2.25%3.17%3.42%1 Month Performance22.22%3.41%4.34%1.09%1 Year Performance-42.48%18.61%44.12%23.84% Zentalis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZNTLZentalis Pharmaceuticals1.9582 of 5 stars$1.76-3.3%$8.20+365.9%-40.3%$131.29M$67.43M-0.78160ANABAnaptysBio1.9248 of 5 stars$20.10-0.6%$46.13+129.5%-44.6%$566.10M$91.28M-4.49100Positive NewsSVRASavara2.4548 of 5 stars$3.14-0.6%$6.17+96.4%-23.8%$546.17MN/A-6.2820SAGESage Therapeutics3.6921 of 5 stars$8.68flat$7.85-9.6%N/A$543.54M$41.24M-1.78690News CoverageRAPPRapport Therapeutics1.7878 of 5 stars$14.63-0.9%$29.50+101.6%-26.6%$539.07MN/A-5.85N/APositive NewsGap UpKODKodiak Sciences3.7906 of 5 stars$9.47-7.2%$11.75+24.1%+253.8%$538.78MN/A-2.4990ARVNArvinas3.9166 of 5 stars$7.48+2.2%$19.76+164.2%-68.6%$537.42M$263.40M-7.41420Positive NewsSEPNSepterna1.6995 of 5 stars$11.96-0.3%$26.75+123.7%N/A$534.58M$1.08M-1.19N/AGOSSGossamer Bio3.8006 of 5 stars$2.36+0.9%$8.50+260.2%+169.2%$532.07M$114.70M-3.81180ZVRAZevra Therapeutics3.3853 of 5 stars$9.36-0.8%$23.71+153.4%+29.8%$529.91M$23.61M-44.5720OPTOpthea0.3947 of 5 stars$3.41+7.2%$1.33-60.9%+16.0%$524.85M$120K0.008Upcoming EarningsGap UpHigh Trading Volume Related Companies and Tools Related Companies ANAB Competitors SVRA Competitors SAGE Competitors RAPP Competitors KOD Competitors ARVN Competitors SEPN Competitors GOSS Competitors ZVRA Competitors OPT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZNTL) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access